SEC Filing Summary: PerkinElmer, Inc. (Form 10-K)
Business Context and Reporting Period
This filing covers the fiscal year ended January 1, 2006 for PerkinElmer, Inc. (Note: The input metadata references "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.). The company operates in two primary reporting segments: Life and Analytical Sciences (drug discovery, genetic screening, environmental analysis) and Optoelectronics (digital imaging, sensors, specialty lighting). The company is headquartered in Wellesley, Massachusetts, and markets products in over 125 countries.
Key Financial Metrics
- Revenue (Continuing Operations): $1,473.8 million (up 3% from $1,429.1 million in 2004).
- Operating Income (Continuing Operations): $140.95 million (up 2% from $137.68 million in 2004).
- Net Income: $268.1 million (driven significantly by gains on discontinued operations).
- Diluted Earnings Per Share: $2.04.
- Gross Margin: 41.7% (up 90 basis points from 40.8% in 2004).
- Operating Cash Flow (Continuing): $193.4 million.
- Debt: Long-term debt decreased to $243.3 million; Short-term debt was $1.1 million. The company repurchased approximately $270 million of Senior Subordinated Notes in late 2005.
- Liquidity: Cash and cash equivalents totaled $502.3 million as of January 1, 2006.
Material Changes vs. Prior Period
- Discontinued Operations: The company divested its Fluid Sciences segment (Aerospace and Fluid Testing businesses), generating a net pre-tax gain of $280.9 million. It also sold the Lithography business (loss of $3.3 million) and shut down the Fiber Optics Test Equipment business (loss of $5.2 million).
- Segment Performance: Life and Analytical Sciences sales grew 2% to $1,081.1 million. Optoelectronics sales grew 7% to $392.7 million, aided by the acquisition of Elcos AG.
- Restructuring: Total restructuring and integration charges were $22.1 million in 2005, compared to zero in 2004. This included charges for workforce reductions and facility closures.
- Tax Matters: The effective tax rate on continuing operations dropped to 0.19% (from 23.6% in 2004) due to a $27.5 million benefit from the resolution of tax audits and the use of tax attributes enabled by the sale of the Fluid Sciences business.
Guidance, Outlook, and Risks
- Capital Allocation: The company reaffirmed a share repurchase program for up to 10 million shares. It also entered a new $350 million unsecured senior revolving credit facility.
- Outlook: Management expects R&D spending to increase in 2006. Capital expenditures are expected to be between $35 million and $45 million for 2006.
- Accounting Changes: The company adopted SFAS No. 123(R) effective January 1, 2006, requiring fair-value accounting for share-based payments, estimated to impact 2006 earnings by approximately 6 cents per share.
- Risks: Key risks include the ability to introduce new products, competition, foreign exchange fluctuations (61% of sales are international), and intellectual property litigation (specifically ongoing disputes with Enzo Biochem and Amersham Biosciences).
Investor Verification Checklist
- Verify the sustainability of the 2005 net income, which was heavily influenced by one-time gains from discontinued operations ($186.4 million net gain).
- Monitor the resolution of ongoing intellectual property litigation with Enzo Biochem and Amersham Biosciences, as outcomes could result in significant liabilities.
- Assess the impact of the new SFAS 123(R) standard on future reported earnings and cash flows.
- Review the progress of the divestiture of the Semiconductor business (sold Feb 2006) to confirm the final gain calculation.
- Track the execution of the $22.1 million restructuring plan and associated cash outflows in 2006.